Impact News +++ Vorabbekanntmachung Finanzberichte News: 3U HOLDING AG (EQS) +++ 3U HOLDING Aktie +3,49%

Q32 BIO Aktie

>Q32 BIO Aktienkurs

3.58 EUR +8.5% (Tradegate)

Ask: 3.56 EUR / 1680 Stück

Bid: 3.44 EUR / 1750 Stück

Tagesumsatz: 265 Stück

Realtime Kurs von 7:30 bis 22 Uhr!

Q32 BIO Aktie über LYNX handeln

Intraday

1 Jahr

>Q32 BIO Performance

1 Woche: +80,2%

1 Monat: +34,4%

3 Monate: +124,7%

6 Monate: +113,7%

1 Jahr: -87,2%

laufendes Jahr: +2,5%

>Q32 BIO Aktie

Name:

Q32 BIO INC. O.N.

Land:

USA

Sektor:

Gesundheit

ISIN/ Wkn:

US7469641051 / A4ZZ0Z

Symbol/ Ticker:

DB0 (Frankfurt) / QTTB (NASDAQ)

Kürzel:

FRA:DB0, ETR:DB0, DB0:GR, NASDAQ:QTTB

Index:

Webseite:

https://www.q32bio.com/

Profil:

Q32 Bio Inc., a clinical-stage biotechnology compa..
>Volltext..

Marktkapitalisierung:

23.21 Mio. EUR

Unternehmenswert:

-4.07 Mio. EUR

Umsatz:

EBITDA:

-37.1 Mio. EUR

Nettogewinn:

-36.26 Mio. EUR

Gewinn je Aktie:

-2.97 EUR

Schulden:

14.66 Mio. EUR

Liquide Mittel:

42.23 Mio. EUR

Operativer Cashflow:

-33.41 Mio. EUR

Bargeldquote:

4.41

Umsatzwachstum:

Gewinnwachstum:

19.57%

Dividende je Aktie:

Dividendenrendite:

Dividendenschätzung:

Insiderhandel:

Suchwörter:

Q32 BIO

Letzte Datenerhebung:

02.12.25

>Q32 BIO Kennzahlen

Aktien/ Unternehmen:

Aktien: 12.3 Mio. St.

Frei handelbar: 37.01%

Leerverk. Aktien: 2.26%

Rückkaufquote: -1.18%

Mitarbeiter: 42

Umsatz/Mitarb.: -

Analysten:

Analystenrating: Buy

Kursziel: 232.47%

Bewertung:

KGV: -

KGV lG: -

KUV: -

KBV: -

PEG-Ratio: -

EV/EBITDA: -

Rentabilität:

Bruttomarge: -

Gewinnmarge: -

Operative Marge: -

Managementeffizenz:

Gesamtkaprendite: -51.87%

Eigenkaprendite: -

>Q32 BIO Peer Group

Es sind 599 Aktien bekannt.

>Q32 BIO Chart & Kurs - NASDAQ

>Q32 BIO News

01.12.25 - 14:36	Q32 Bio: Aktie schießt nach Verkauf von Phase-2-Komplementinhibitor an Akebia in die Höhe (Investing.com DE)
	Um den gesamten Artikel unter de.investing.com zu lesen, klicken Sie bitte auf die Überschrift...

01.12.25 - 13:03	Q32 Bio Sells Complement Inhibitor ADX-097 (PR Newswire)
	-- Asset sale further enables Company's strategic focus on advancing bempikibart for alopecia areata -- -- $12 million in upfront and guaranteed near-term milestone payments expected to extend cash runway into the second half of 2027 -- -- Eligible to receive up to a total of $592 million......

01.12.25 - 13:03	Akebia Announces Establishment of Rare Kidney Disease Pipeline (GlobeNewswire EN)
	Acquires next generation tissue-targeted C3d-Factor H fusion protein complement inhibitor from Q32 Bio...

13.11.25 - 13:30	Q32 Bio GAAP EPS of -$0.60 beats by $0.59 (SeekingAlpha)
	Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...

13.11.25 - 13:01	Q32 Bio Reports Third Quarter 2025 Financial Results and Provides Corporate Update (PR Newswire)
	-- Completed enrollment in Part B of SIGNAL-AA Phase 2a clinical trial and increased trial size to 33 patients based on patient demand; topline data readout expected in mid-2026 -- -- Dosing of patients in Part A open-label extension (OLE) ongoing -- -- Cash and cash equivalents of $49.0......

21.10.25 - 13:01	Q32 Bio Announces Completion of Enrollment in Part B of SIGNAL-AA Phase 2a Clinical Trial of Bempikibart for Alopecia Areata (PR Newswire)
	-- SIGNAL-AA Part B exceeded target enrollment based on demand from patients; trial size increased to 33 patients -- WALTHAM, Mass., Oct. 21, 2025 /PRNewswire/ -- Q32 Bio Inc. (NASDAQ: QTTB) ("Q32 Bio"), a clinical stage biotechnology company focused on developing innovative therapies for......

29.08.25 - 05:01	Insiderhandel: Chief Scientific Officer verkauft Aktien von Q32 Bio im Wert von 5385 USD (Insiderkauf)
	Violette, Shelia M. - Vorstand - Tag der Transaktion: 2025-08-26...

29.08.25 - 05:01	Insiderhandel: CEO verkauft Aktien von Q32 Bio im Wert von 18900 USD (Insiderkauf)
	Morrison, Jodie Pope - Vorstand - Tag der Transaktion: 2025-08-26...

29.08.25 - 05:01	Insiderhandel: CFO and President verkauft Aktien von Q32 Bio im Wert von 7636 USD (Insiderkauf)
	Kalowski, Lee - Vorstand - Tag der Transaktion: 2025-08-26...

28.08.25 - 13:03	Q32 Bio to Participate in the 2025 Wells Fargo Healthcare Conference (PR Newswire)
	WALTHAM, Mass., Aug. 28, 2025 /PRNewswire/ -- Q32 Bio Inc. (Nasdaq: QTTB) ("Q32 Bio"), a clinical stage biotechnology company focused on developing innovative therapies for alopecia areata (AA) and other autoimmune and inflammatory diseases, today announced that management will......

06.08.25 - 20:36	Q32 Bio (QTTB) Q2 Loss Drops 45% (Fool)
	Um den gesamten Artikel unter fool.com zu lesen, klicken Sie bitte auf die Überschrift...

06.08.25 - 13:51	Q32 Bio GAAP EPS of -$0.78 (SeekingAlpha)
	Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...

11.07.25 - 14:18	Pre-market Movers: Above Food Ingredients, Future FinTech Group, LM Funding America, Capricor Therapeutics, Q32 Bio (AFX)
	OTTAWA (dpa-AFX) - The following are some of the stocks making big moves in Friday's pre-market trading (as of 07.15 A.M. ET).In the Green Above Food Ingredients Inc. (ABVE) is up over 115% at $3.......

25.06.25 - 13:54	Q32 Bio names interim chief medical officer (SeekingAlpha)
	Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...

25.06.25 - 13:01	Q32 Bio Appoints Adrien Sipos, M.D., Ph.D., as Interim Chief Medical Officer (PR Newswire)
	-- Dr. Sipos is an immunologist and seasoned Immunology and Inflammation (I&I) drug developer, with over 25 years of clinical development and medical affairs leadership experience -- WALTHAM, Mass., June 25, 2025 /PRNewswire/ -- Q32 Bio Inc. (Nasdaq: QTTB) ("Q32 Bio"), a clinical stage......

16.04.25 - 13:01	Q32 Bio Doses First Patients in Both Part A Open-Label Extension and Part B of SIGNAL-AA Phase 2a Trial Evaluating Bempikibart in Alopecia Areata (PR Newswire)
	-- SIGNAL-AA Part B topline data readout on-track for 1H'26 -- WALTHAM, Mass., April 16, 2025 /PRNewswire/ -- Q32 Bio Inc. (Nasdaq: QTTB) ("Q32 Bio" or the "Company"), a clinical stage biotechnology company focused on developing innovative therapies for alopecia areata and other......

08.04.25 - 19:45	All You Need to Know About Q32 Bio (QTTB) Rating Upgrade to Buy (Zacks)
	Q32 Bio (QTTB) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy)....

11.03.25 - 12:30	Q32 Bio GAAP EPS of -$1.16 beats by $0.37 (SeekingAlpha)
	Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...

11.03.25 - 12:01	Q32 Bio Reports Fourth Quarter 2024 Financial Results and Provides Corporate Update (PR Newswire)
	-- Presented bempikibart SIGNAL-AA Phase 2a Part A alopecia areata (AA) data demonstrating encouraging clinical activity and highlighting the potential to be a differentiated treatment as a late-breaking oral presentation at the 2025 American Academy of Dermatology (AAD) Annual Meeting --......

08.03.25 - 17:00	Q32 Bio Presents Results from SIGNAL-AA Part A Clinical Trial Evaluating Bempikibart in Patients with Alopecia Areata at the 2025 American Academy of Dermatology Meeting (PR Newswire)
	-- Results presented in AAD late-breaker demonstrate bempikibart's encouraging improvement on SALT reduction at week 24 and continued effects after dosing cessation in patients with severe and very severe alopecia areata (AA) -- -- Durable, ongoing responses in multiple patients through......

>weitere News anzeigen...

>Impressum >Über uns >Datenschutz >Financial Data & Solutions

>Behalte deine Investments mit realtime Kursen & News im Blick. Finde neue spannende Aktien! Registriere Dich und werde Mitglied!

Zitat des Tages: Der Blitz trifft den, der rennt. - Sprichwort Ungarn

Partner: >Tradegate Börse | >Dukascopy | >Boersentreff- Partner

Börsentreff auf Facebook |

Börsentreff auf X |

Börsentreff auf Instagram